Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
about
Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysisRisk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9Hormonal contraception and venous thromboembolismVenous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10Third generation oral contraceptives and risk of venous thrombosis: meta-analysisThe progestin levonorgestrel induces endothelium-independent relaxation of rabbit jugular vein via inhibition of calcium entry and protein kinase C: role of cyclic AMPTamoxifen and risk of idiopathic venous thromboembolismEvolution of primary care databases in UK: a scientometric analysis of research outputDrospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies.International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study).Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives.Mechanism of action of the levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding.Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptivesBenefits and risks of third-generation oral contraceptives.Oral contraception was not associated with venous thromboembolic disease in recent study.Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed.Pitfalls of pharmacoepidemiologyDoH seems to have underestimated incidence of venous thromboembolism in users of combined oral contraceptives.Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.Pharmacodynamics of oestrogens and progestogens.Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism.Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.Oral contraceptives, hormone replacement therapy and haemostasis.Contraception: what has changed over the past decade?Venous thromboembolism in women taking hormonal contraceptives.The long term health consequences of polycystic ovary syndrome.The association between drospirenone and hyperkalemia: a comparative-safety studyEvaluating primary care groups.The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy.New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control.Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study.The prescription of isotretinoin to women: is every precaution taken?Current reversible contraceptive methods: a global perspective.Update in women's health for the general internist.Hormonal contraception and thrombotic risk: a multidisciplinary approach.Diane-35 (cyproterone acetate): safety concernsHormone replacement therapy and venous thromboembolism.Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology
P2860
Q24527283-206FE8C7-C6A6-49A0-A45A-26A1096D3CDBQ24622035-86DB684D-C7AC-4333-BFA5-D9E377CEBE99Q24634077-B9D9352A-C8E7-4904-B17E-1BF95EF128E8Q28266187-EDDC81E6-7C27-40A3-BD16-BE80E92A5CD0Q28266410-EDBBC081-998D-47F3-8841-056F682A51B8Q28344562-F4548493-DE4A-4EC0-8781-FA8C74D4C9D1Q28344628-CD7550C5-033D-437C-B663-8CECA8528BFBQ28368257-7296AE68-E87C-4DCF-A3A9-C5889DDD9540Q28552854-6FA91B41-B542-41AF-B94F-2DCDBE4CE530Q30235365-10EF6F79-63FF-4952-92A0-D7E88A3AE081Q30891586-9B52BD99-1D14-4EA5-B6AC-E33693A5A2EAQ32067110-C02FE263-4E7F-47F6-97EB-54F51E89D4F4Q33410272-7DFFF697-E0AA-4068-BB5D-2B8D8E2CA8C6Q33704721-8494270C-F424-4092-8FB3-29D8213D1508Q33778866-4CFBA4BB-BD77-4B77-8DD7-C4BF53E3902DQ33789636-64734537-CEB3-4476-A158-F4A13D3EBB2FQ33799389-F3206D0A-949F-4F62-9CB6-370B804BFC9EQ33803070-EE2E6255-3B62-4CBC-83FE-1E9FC9299823Q33816390-63226243-841A-4B5B-A5E2-EA9D908E3028Q33879375-02CF1DAF-ADA3-4F6A-BB7C-E28759F64A73Q33918549-20575290-B7B9-4B0E-AA8D-37B334E26B20Q33932536-45FCD123-5D37-4659-AFFB-9C8A8F5E8BE2Q33954905-25E8009B-EAAF-46B7-954A-AC4A3EE4D275Q34039827-B191ADA5-3CAA-4247-B7DB-174D59E3A483Q34070597-6E984007-2294-4D58-B2C5-C7D41A002995Q34097184-C3038461-A5DD-4EEA-8FF6-7B5FC96F7DB6Q34105196-BDA5CAAC-65DB-40CE-BEB7-B2B28037FB8AQ34114759-F3E9F25A-7EF9-4498-85CA-11E9D99EC8DCQ34215830-0A27E5B2-E716-44C3-97D8-76F6EA7CFEA5Q34215860-025BD4F2-53A1-441F-85AB-71CC08F11E25Q34227082-5AF98714-E663-465A-A981-EF6A18120595Q34272169-DA7FEEF8-1BD2-4C0C-A0C5-34A67FEA4DAFQ34288033-385F3084-24F3-4D2F-9050-9EBD47091D8DQ34467497-2DA9D415-618C-42C4-9ED1-B849AE321DC8Q34478867-5C68F182-BC93-4EAF-BA4F-723BCD2F3F8BQ34482554-6845BD11-7713-46A1-8DB1-7331A50215C7Q34513007-836C09D1-B60F-41F9-8C0C-2B0BF003BEFCQ34536900-A2A53BDA-05BC-45B9-9FAE-0B6AA0D09857Q34575172-00DF7ADD-F122-49A1-9158-9E0ADD966DD5Q34588375-ECC14C36-8B14-4B21-8F3B-7047AFE8B26C
P2860
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Risk of idiopathic cardiovascu ...... fering progestagen components.
@en
type
label
Risk of idiopathic cardiovascu ...... fering progestagen components.
@en
prefLabel
Risk of idiopathic cardiovascu ...... fering progestagen components.
@en
P2093
P1433
P1476
Risk of idiopathic cardiovascu ...... fering progestagen components.
@en
P2093
P304
P356
10.1016/S0140-6736(95)91928-7
P407
P50
P577
1995-12-01T00:00:00Z